Literature DB >> 19360907

Dopaminergic activity in depressed smokers: a positron emission tomography study.

Usoa E Busto1, Laura Redden, Helen Mayberg, Shitij Kapur, Sylvain Houle, Laurie A Zawertailo.   

Abstract

Tobacco dependence is highly prevalent in depressed patients. We assessed changes in [(11)C]-raclopride binding potential (BP) using positron emission tomography (PET) before and after the oral administration of d-amphetamine in healthy controls and unmedicated patients with current depression with and without current tobacco dependence. Over a single study day 2 [(11)C]-raclopride positron emission tomography scans were taken in 38 subjects: at baseline and 2 h following oral d-amphetamine 30 mg. Twenty controls (9 smokers, 11 nonsmokers) and 18 subjects with current major depressive episode (8 smokers, 10 non-smokers). Striatal [(11)C]-raclopride binding potential was measured before and after d-amphetamine administration. Depressed smokers had a lower baseline [(11)C]-raclopride binding potential compared with both control non-smokers (P < 0.007) and depressed non-smokers (P < 0.001). There was a main effect of smoking status on amphetamine-induced change in [(11)C]-raclopride binding potential (P < 0.02), but no main effect of depression. This may be due to a floor effect because of the low BP at baseline. Depressed subjects reported significant increase of positive mood after d-amphetamine administration compared with controls (depressed smokers vs. control smokers: P < 0.05; depressed non-smokers vs. controls: P < 0.055). Tobacco dependence appears to decrease d-amphetamine-induced changes in [(11)C]-raclopride binding potential as measured by positron emission tomography. Comorbid major depression and tobacco dependence exacerbates this effect, suggesting an altered dopamine system in comorbid patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19360907      PMCID: PMC2761223          DOI: 10.1002/syn.20646

Source DB:  PubMed          Journal:  Synapse        ISSN: 0887-4476            Impact factor:   2.562


  49 in total

Review 1.  Utility of subjective-effects measurements in assessing abuse liability of drugs in humans.

Authors:  M W Fischman; R W Foltin
Journal:  Br J Addict       Date:  1991-12

2.  Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats.

Authors:  G Di Chiara; A Imperato
Journal:  Proc Natl Acad Sci U S A       Date:  1988-07       Impact factor: 11.205

3.  Smoking, smoking cessation, and major depression.

Authors:  A H Glassman; J E Helzer; L S Covey; L B Cottler; F Stetner; J E Tipp; J Johnson
Journal:  JAMA       Date:  1990-09-26       Impact factor: 56.272

4.  Nicotine-induced dopamine release in primates measured with [11C]raclopride PET.

Authors:  Stefano Marenco; Richard E Carson; Karen Faith Berman; Peter Herscovitch; Daniel R Weinberger
Journal:  Neuropsychopharmacology       Date:  2004-02       Impact factor: 7.853

5.  The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire.

Authors:  T F Heatherton; L T Kozlowski; R C Frecker; K O Fagerström
Journal:  Br J Addict       Date:  1991-09

6.  The hedonic response to cigarette smoking is proportional to dopamine release in the human striatum as measured by positron emission tomography and [11C]raclopride.

Authors:  Sean P Barrett; Isabelle Boileau; Johanna Okker; Robert O Pihl; Alain Dagher
Journal:  Synapse       Date:  2004-11       Impact factor: 2.562

7.  Major depression and cigarette smoking: results of a 21-year longitudinal study.

Authors:  D M Fergusson; R D Goodwin; L J Horwood
Journal:  Psychol Med       Date:  2003-11       Impact factor: 7.723

8.  Oral D-amphetamine causes prolonged displacement of [11C]raclopride as measured by PET.

Authors:  Laura Cárdenas; Sylvain Houle; Shitij Kapur; Usoa E Busto
Journal:  Synapse       Date:  2004-01       Impact factor: 2.562

Review 9.  Dopamine in drug abuse and addiction: results from imaging studies and treatment implications.

Authors:  N D Volkow; J S Fowler; G-J Wang; J M Swanson
Journal:  Mol Psychiatry       Date:  2004-06       Impact factor: 15.992

10.  Smoking-induced ventral striatum dopamine release.

Authors:  Arthur L Brody; Richard E Olmstead; Edythe D London; Judah Farahi; Jeffrey H Meyer; Paul Grossman; Grace S Lee; Joe Huang; Emily L Hahn; Mark A Mandelkern
Journal:  Am J Psychiatry       Date:  2004-07       Impact factor: 18.112

View more
  24 in total

Review 1.  Neuroimaging reward, craving, learning, and cognitive control in substance use disorders: review and implications for treatment.

Authors:  Jody Tanabe; Michael Regner; Joseph Sakai; Diana Martinez; Joshua Gowin
Journal:  Br J Radiol       Date:  2019-05-14       Impact factor: 3.039

Review 2.  Visualizing epigenetics: current advances and advantages in HDAC PET imaging techniques.

Authors:  C Wang; F A Schroeder; J M Hooker
Journal:  Neuroscience       Date:  2013-09-17       Impact factor: 3.590

3.  Striatal dopamine D2/3 receptor-mediated neurotransmission in major depression: Implications for anhedonia, anxiety and treatment response.

Authors:  Marta Peciña; Magdalena Sikora; Erich T Avery; Joseph Heffernan; Susana Peciña; Brian J Mickey; Jon-Kar Zubieta
Journal:  Eur Neuropsychopharmacol       Date:  2017-09-01       Impact factor: 4.600

4.  A linear model for estimation of neurotransmitter response profiles from dynamic PET data.

Authors:  Marc D Normandin; Wynne K Schiffer; Evan D Morris
Journal:  Neuroimage       Date:  2011-07-13       Impact factor: 6.556

Review 5.  A review of positron emission tomography studies exploring the dopaminergic system in substance use with a focus on tobacco as a co-variate.

Authors:  Thulasi Thiruchselvam; Saima Malik; Bernard Le Foll
Journal:  Am J Drug Alcohol Abuse       Date:  2016-11-30       Impact factor: 3.829

Review 6.  Imaging addiction: D2 receptors and dopamine signaling in the striatum as biomarkers for impulsivity.

Authors:  Pierre Trifilieff; Diana Martinez
Journal:  Neuropharmacology       Date:  2013-07-10       Impact factor: 5.250

7.  Cigarette smoking modulates medication-associated deficits in a monetary reward task in patients with schizophrenia.

Authors:  Birgit Lernbass; Georg Grön; Nadine D Wolf; Birgit Abler
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2012-09-26       Impact factor: 5.270

8.  Antidepressant response to aripiprazole augmentation associated with enhanced FDOPA utilization in striatum: a preliminary PET study.

Authors:  Charles R Conway; John T Chibnall; Paul Cumming; Mark A Mintun; Marie Anne I Gebara; Dana C Perantie; Joseph L Price; Martha E Cornell; Jonathan E McConathy; Sunil Gangwani; Yvette I Sheline
Journal:  Psychiatry Res       Date:  2014-01-14       Impact factor: 3.222

Review 9.  Dual role of nicotine in addiction and cognition: a review of neuroimaging studies in humans.

Authors:  Agnes J Jasinska; Todd Zorick; Arthur L Brody; Elliot A Stein
Journal:  Neuropharmacology       Date:  2013-03-06       Impact factor: 5.250

10.  Dopamine Release in Antidepressant-Naive Major Depressive Disorder: A Multimodal [11C]-(+)-PHNO Positron Emission Tomography and Functional Magnetic Resonance Imaging Study.

Authors:  Franklin R Schneier; Mark Slifstein; Alexis E Whitton; Diego A Pizzagalli; Jenna Reinen; Patrick J McGrath; Dan V Iosifescu; Anissa Abi-Dargham
Journal:  Biol Psychiatry       Date:  2018-05-25       Impact factor: 13.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.